Evidence map›Paper›PMID 31031042›Full record

ArticleEuropean urology focus2020

Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance.

Liam C Macleod, Jonathan G Yabes, Mina M Fam, Jathin Bandari, Michelle Yu, Avinash Maganty, Alessandro Furlan, Christopher P Filson, Benjamin J Davies, Bruce L Jacobs

Open access · greenAbstract read
In one paragraph

Article in European urology focus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Liam C MacleodDepartment of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address: macleodl2@upmc.edu.
Jonathan G YabesDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Mina M FamJersey Shore University Medical Center, Neptune, NJ, USA.
Jathin BandariDepartment of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Michelle YuDepartment of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Avinash MagantyDepartment of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Alessandro FurlanDepartment of Radiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Christopher P FilsonDepartment of Urology, Emory University, Atlanta, GA, USA.
Benjamin J DaviesDepartment of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Bruce L JacobsDepartment of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
University of Pittsburgh Medical Center · USEmory University · USJersey Shore University Medical Center · USUniversity of Pittsburgh · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
NCI NIH HHS P30 CA047904
6 · The paper itself

Abstract

backgroundMultiparametric magnetic resonance imaging (mpMRI) may improve prostate cancer risk stratification and decrease the need for repeat biopsies in men on prostate cancer active surveillance (AS). However, the impact of mpMRI on AS-related healthcare spending has not been established.

objectiveTo characterize the impact of mpMRI on AS-related Medicare expenditures. DESIGN, SETTING, AND

participantsUsing Surveillance, Epidemiology, and End Results (SEER)-Medicare files, we identified men ≥66 yr old with localized prostate cancer diagnosed during 2008-2013. OUTCOME MEASURES AND STATISTICAL ANALYSIS: With a validated algorithm, we classified men into AS with and without mpMRI groups. We then determined Medicare spending on AS in each group using inflation-adjusted, price-standardized Medicare payments for AS-related procedures (ie, prostate-specific antigen [PSA] tests, prostate biopsies, biopsy complications, and mpMRI). Multivariable median regression compared Medicare spending on AS for men who received mpMRI and those who did not. RESULTS AND LIMITATIONS: We identified 9081 men on AS with a median follow-up of 45 mo (interquartile range 29-64 mo). Thirteen percent (N = 1225) received mpMRI. On multivariable median regression, receipt of mpMRI was associated with an additional $447 (95% confidence interval $409-487) in Medicare spending per year. We observed greater frequency of AS-related procedures and higher spending for identical procedures (eg, PSA or prostate biopsy) in the mpMRI group than in the non-mpMRI group (all p <  0.001).

conclusionsAmong Medicare beneficiaries on AS, mpMRI is associated with additional annual Medicare spending. Future studies are needed to determine optimal use of mpMRI during AS to maximize value. PATIENT SUMMARY: Prostate magnetic resonance imaging (MRI) helps physicians determine which prostate cancers are aggressive and which can be monitored safely. We studied whether using MRI during prostate cancer monitoring (also called active surveillance) resulted in increased healthcare spending. There was a modest increase in spending, but this may be worthwhile if the use of MRI allows physicians to monitor prostate cancer more accurately.

Indexed as

Health ExpendituresMedicareAgedAged, 80 and overCohort StudiesHumansMaleMultiparametric Magnetic Resonance ImagingProstatic NeoplasmsUnited StatesWatchful WaitingHealth services researchMagnetic resonance imagingMedicareProstatic neoplasmsSurveillanceSurveillance, Epidemiology, and End Results program

Identifiers

PMID31031042
PMCPMC6814515
OpenAlexW2941281880

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.